Ovarian cancer immunotherapy: opportunities, progresses and challenges

被引:0
作者
Bei Liu
John Nash
Carolyn Runowicz
Helen Swede
Richard Stevens
Zihai Li
机构
[1] University of Connecticut School of Medicine,Department of Immunology
[2] University of Connecticut School of Medicine,Neag Comprehensive Cancer Center
[3] University of Connecticut School of Medicine,Department of Community Medicine & Health Care
来源
Journal of Hematology & Oncology | / 3卷
关键词
Ovarian Cancer; Treg Cell; Epithelial Ovarian Cancer; Dendritic Cell Vaccine; Tumor Cell Vaccine;
D O I
暂无
中图分类号
学科分类号
摘要
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
引用
收藏
相关论文
共 600 条
[1]  
Zhang L(2003)Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 203-213
[2]  
Conejo-Garcia JR(2008)Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecol Oncol 108 415-420
[3]  
Katsaros D(2005)Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 18538-18543
[4]  
Gimotty PA(2004)Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942-949
[5]  
Massobrio M(2008)Immunotherapy opportunities in ovarian cancer Expert Rev Anticancer Ther 8 243-257
[6]  
Regnani G(2004)The three Es of cancer immunoediting Annu Rev Immunol 22 329-360
[7]  
Makrigiannakis A(2004)The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning Cancer Immunity 4 5-20
[8]  
Gray H(1995)Human neoplasms elicit multiple specific immune responses in the autologous host Proc Natl Acad Sci USA 92 11810-11813
[9]  
Schlienger K(2008)Harnessing the immune system for ovarian cancer therapy Am J Reprod Immunol 59 62-74
[10]  
Liebman MN(2005)The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer Clin Cancer Res 11 8326-8331